Novel drug targets for asthma and COPD: Lessons learned from in vitro and in vivo models

Katie E. Baker, Sara J. Bonvini, Chantal Donovan, Rachel E. Foong, Bing Han, Aruni Jha, Yasin Shaifta, Marieke Smit, Jill R. Johnson, Lyn M. Moir*

*Corresponding author voor dit werk

OnderzoeksoutputAcademicpeer review

28 Citaten (Scopus)

Samenvatting

Asthma and chronic obstructive pulmonary disease (COPD) are highly prevalent respiratory diseases characterized by airway inflammation, airway obstruction and airway hyperresponsiveness. Whilst current therapies, such as beta-agonists and glucocorticoids, may be effective at reducing symptoms, they do not reduce disease progression. Thus, there is a need to identify new therapeutic targets. In this review, we summarize the potential of novel targets or tools, including anti-inflammatories, phosphodiesterase inhibitors, kinase inhibitors, transient receptor potential channels, vitamin D and protease inhibitors, for the treatment of asthma and COPD. (C) 2014 Published by Elsevier Ltd.

Originele taal-2English
Pagina's (van-tot)181-198
Aantal pagina's18
TijdschriftPulmonary Pharmacology & Therapeutics
Volume29
Nummer van het tijdschrift2
DOI's
StatusPublished - dec.-2014

Vingerafdruk

Duik in de onderzoeksthema's van 'Novel drug targets for asthma and COPD: Lessons learned from in vitro and in vivo models'. Samen vormen ze een unieke vingerafdruk.

Citeer dit